Press Releases
AstraZeneca provides update on Phase III trial of Selumetinib...
 AstraZeneca announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib, in combination with docetaxel chemotherapy as 2nd-line treatment in...
Press Releases
Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company
Biogen announced that Bioverativ will be the name of the standalone, publicly-traded global biotechnology company that it expects to launch in early 2017. Bioverativ will...
Press Releases
Takeda Receives Marketing Authorization in Canada for NINLAROâ„¢ (ixazomib)...
Takeda Pharmaceutical Company Limited announced Takeda Canada has received approval from Health Canada for NINLAROâ„¢ (ixazomib) capsules in combination with lenalidomide and dexamethasone for the...
Press Releases
FDA Approves Mercks KEYTRUDA® for Patients with Recurrent or...
Merck known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s...
Press Releases
Teva Announces Launch of Generic Gleevec® Tablets in the...
Teva Pharmaceutical Industries Ltd announced the launch of the generic equivalent to Gleevec®1(imatinib mesylate) tablets,100 mg and 400 mg, in the United States for multiple...
Press Releases
Momenta Discontinues Further Accrual of its Phase 2 Trial...
 The decision to discontinue enrollment into the study was based on the recommendation from the independent Data Safety Monitoring Board (DSMB) following a...
Press Releases
Novartis CDK4/6 inhibitor LEE011 receives FDA Breakthrough Therapy designation...
Novartis announced today that the US FDA has granted Breakthrough Therapy designation to LEE011 (ribociclib), in combination with letrozole, for the treatment of hormone receptor...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.